老年卵巢癌幸存者报告的长期健康相关生活质量低于年轻幸存者:一项基于人群的profiles登记研究
该研究纳入2000至2010年确诊的348例卵巢癌幸存者,2012年采用EORTC QLQ-C30问卷评估健康相关生活质量(HRQoL),191例(55%)完成问卷,其中≥70岁者占31%(n=59)。与年龄匹配的常模人群相比,≥70岁幸存者在总体健康状况和除情绪功能外的所有功能子量表得分更低、症状更多;<70岁幸存者仅躯体功能和认知功能较差。年龄可调节化疗对HRQoL的影响。
要点
- ≥70岁卵巢癌幸存者较年龄匹配常模人群总体健康状况及除情绪功能外所有功能子量表得分更低、症状更多。
- <70岁幸存者仅躯体功能和认知功能较常模人群差。
- 年龄可调节化疗对HRQoL的影响:老年化疗者躯体功能更好、疼痛和失眠更少,年轻幸存者相反。
核心结论
- 与年龄匹配的常模人群相比,老年卵巢癌幸存者报告的HRQoL得分低于年轻幸存者。
- 由于这代表长期幸存者的选择,未来研究应关注从诊断到治疗及随访全程的HRQoL轨迹,以识别与整个老年卵巢癌人群较差HRQoL相关的因素,以及及时干预能否改善HRQoL。
研究设计与样本
- 基于荷兰Eindhoven癌症登记处的人群登记研究,邀请2000至2010年确诊的卵巢癌幸存者(n=348)于2012年完成EORTC QLQ-C30 HRQoL问卷。
- 将幸存者HRQoL与年龄匹配的常模人群比较,并将老年幸存者(≥70岁)与年轻幸存者比较。
主要发现
- 问卷回收191例(55%),其中31%为≥70岁(n=59)。
- 与常模人群相比,≥70岁幸存者在总体健康状况和除情绪功能外的所有功能子量表得分更低,并报告更多症状。
- <70岁幸存者与常模人群相比仅报告躯体功能和认知功能更差。
- 多数差异为中等至小的临床相关性。
- 年龄似乎调节化疗对HRQoL的影响:接受化疗的老年幸存者躯体功能更好、疼痛和失眠更少,而年轻幸存者则相反。
局限性
- 由于这代表长期幸存者的选择,未来研究应关注从诊断到治疗及随访全程的HRQoL轨迹,以识别与整个老年卵巢癌人群较差HRQoL相关的因素,以及及时干预能否改善HRQoL。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess long-term differences in health-related quality of life (HRQoL) of older ovarian cancer survivors compared to both an age-matched normative population and to younger survivors. In addition, the differential effect of chemotherapy on HRQoL between older and younger survivors was compared. METHODS: Ovarian cancer survivors (n = 348) diagnosed between 2000 and 2010, as registered by the Dutch population-based Eindhoven Cancer Registry, were invited to complete the EORTC QLQ-C30 HRQoL questionnaire in 2012. HRQoL outcomes of survivors were compared with an age-matched normative population and older survivors (≥70 years) were compared with younger survivors. RESULTS: The questionnaire was returned by 191 ovarian cancer survivors (55%), 31% were aged ≥70 years (n = 59). Compared to the normative population, survivors ≥70 years scored lower on global health status and all functioning subscales except emotional functioning, and they reported more symptoms. Survivors aged <70 years only reported worse physical and cognitive functioning in comparison with the normative population. Most differences were of medium to small clinical relevance. Age appeared to moderate the effect of chemotherapy on HRQoL. Older survivors who had received chemotherapy experienced better physical functioning and less pain and insomnia while the opposite was found in younger survivors. CONCLUSION: In comparison with an age-matched normative population, older ovarian cancer survivors report lower HRQoL scores than younger survivors. As this represents a selection of long-term survivors, future research should focus on the trajectory of HRQoL from diagnosis throughout treatment and follow-up to identify which factors are related to worse HRQoL in the entire older ovarian cancer population and whether timely interventions are able to improve HRQoL.
引用
- van Walree IC, Hamaker ME, van de Poll-Franse LV, et al. Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry. Gynecol Oncol. 2019. PMID: 30772033. doi:10.1016/j.ygyno.2019.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。